IP Library Granted Patent US 9,320,796
Granted Patent B2
US 9,320,796 · App. 14/790,113 · Granted Apr 26, 2016

Methods and compositions for self-regulated release of active pharmaceutical ingredient

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,320,796
App. No.
14/790,113
Granted
Apr 26, 2016
Kind
B2
Abstract

An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Claims (10)

1. An abuse deterrent pharmaceutical composition comprising an immediate release unit dose of:

a. a pharmaceutically active ingredient;

b. an acid soluble ingredient comprising a cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate, wherein the acid soluble ingredient is present in an amount of about 1 wt % to about 50 wt %; and

c. a buffering ingredient comprising one or more of calcium carbonate, sodium bicarbonate, magnesium oxide, tribasic sodium phosphate, and combinations thereof; wherein the acid soluble ingredient and the buffering ingredient retard release of the pharmaceutically active ingredient when three unit doses or greater of the composition is ingested.

2. The composition of claim 1 , wherein the pharmaceutically active ingredient comprises a drug susceptible to abuse.

3. The composition of claim 1 , wherein the pharmaceutically active ingredient comprises a drug with narrow therapeutic index.

4. The composition of claim 1 , wherein the pharmaceutically active ingredient is contained within a matrix of the acid soluble ingredient.

5. The composition of claim 1 , wherein the pharmaceutically active ingredient is sequestered from the acid soluble ingredient.

6. The composition of claim 1 , wherein the buffering ingredient is present in sufficient amount to elevate stomach pH to greater than 4 when three unit doses or greater of the composition is ingested.

7. The composition of claim 1 , wherein the buffering ingredient is present in an amount of less than about 90 wt %.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2022
From: BRZECZKO, ALBERT W.; HOLLENBECK, R. GARY
To: ACURA PHARMACUETICALS, INC.
Reel/Frame 059186/0374 →
SECURITY INTEREST Recorded Jul 2, 2019
From: ACURA PHARMACEUTICALS, INC.
To: SCHUTTE, JOHN
Reel/Frame 049649/0950 →
SECURITY INTEREST Recorded Jul 2, 2019
From: SCHUTTE, JOHN
To: ABUSE DETERRENT PHARMACEUTICALS, LLC
Reel/Frame 049650/0104 →
RELEASE OF SECURITY INTEREST Recorded Oct 11, 2018
From: OXFORD FINANCE LLC
To: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICALS TECHNOLOGIES, INC.
Reel/Frame 047140/0800 →
SECURITY INTEREST Recorded Mar 17, 2017
From: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICAL TECHNOLOGIES, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 041623/0740 →